Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1955 1
1967 4
1968 1
1969 1
1970 2
1971 4
1972 2
1973 2
1974 5
1975 1
1976 4
1977 3
1978 7
1979 4
1980 5
1981 9
1982 5
1983 6
1984 3
1985 2
1986 4
1987 8
1988 10
1989 9
1990 10
1991 8
1992 6
1993 5
1994 7
1995 7
1996 8
1997 3
1998 8
1999 9
2000 6
2001 12
2002 7
2003 8
2004 9
2005 21
2006 10
2007 9
2008 15
2009 18
2010 16
2011 19
2012 20
2013 26
2014 17
2015 16
2016 17
2017 17
2018 26
2019 24
2020 31
2021 35
2022 31
2023 26
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

556 results

Results by year

Filters applied: . Clear all
Page 1
Chemistry, structure and function of approved oligonucleotide therapeutics.
Egli M, Manoharan M. Egli M, et al. Nucleic Acids Res. 2023 Apr 11;51(6):2529-2573. doi: 10.1093/nar/gkad067. Nucleic Acids Res. 2023. PMID: 36881759 Free PMC article. Review.
Among the diseases targeted by this new class of drugs are homozygous familial hypercholesterolemia, spinal muscular atrophy, Duchenne muscular dystrophy, hereditary transthyretin-mediated amyloidosis, familial chylomicronemia syndrome, acute hepatic porphyria, and primary hyp …
Among the diseases targeted by this new class of drugs are homozygous familial hypercholesterolemia, spinal muscular atrophy, Duchenne muscu …
Therapeutic siRNA: State-of-the-Art and Future Perspectives.
Friedrich M, Aigner A. Friedrich M, et al. BioDrugs. 2022 Sep;36(5):549-571. doi: 10.1007/s40259-022-00549-3. Epub 2022 Aug 23. BioDrugs. 2022. PMID: 35997897 Free PMC article. Review.
Two decades after the discovery of the RNA interference mechanism, the first siRNA drugs received approval for clinical use by the US Food and Drug Administration and the European Medicines Agency between 2018 and 2022. ...Further siRNA drugs are in clinical studies …
Two decades after the discovery of the RNA interference mechanism, the first siRNA drugs received approval for clinical use by the US …
Oxalate homeostasis.
Ermer T, Nazzal L, Tio MC, Waikar S, Aronson PS, Knauf F. Ermer T, et al. Nat Rev Nephrol. 2023 Feb;19(2):123-138. doi: 10.1038/s41581-022-00643-3. Epub 2022 Nov 3. Nat Rev Nephrol. 2023. PMID: 36329260 Free PMC article. Review.
Novel studies have shed light on the essential roles of metabolic pathways, the microbiome, epithelial oxalate transporters, and adequate oxalate excretion to maintain oxalate homeostasis. In patients with primary or secondary hyperoxaluria, nephrolithiasis, acute or chron …
Novel studies have shed light on the essential roles of metabolic pathways, the microbiome, epithelial oxalate transporters, and adequate ox …
Orlistat-associated adverse effects and drug interactions: a critical review.
Filippatos TD, Derdemezis CS, Gazi IF, Nakou ES, Mikhailidis DP, Elisaf MS. Filippatos TD, et al. Drug Saf. 2008;31(1):53-65. doi: 10.2165/00002018-200831010-00005. Drug Saf. 2008. PMID: 18095746 Review.
Interestingly, the use of orlistat has been associated with rare cases of acute kidney injury, possibly due to the increased fat malabsorption resulting from the inhibition of pancreatic and gastric lipase by orlistat, leading to the formation of soaps with calcium and resulting …
Interestingly, the use of orlistat has been associated with rare cases of acute kidney injury, possibly due to the increased fat malabsorpti …
Lumasiran for Advanced Primary Hyperoxaluria Type 1: Phase 3 ILLUMINATE-C Trial.
Michael M, Groothoff JW, Shasha-Lavsky H, Lieske JC, Frishberg Y, Simkova E, Sellier-Leclerc AL, Devresse A, Guebre-Egziabher F, Bakkaloglu SA, Mourani C, Saqan R, Singer R, Willey R, Habtemariam B, Gansner JM, Bhan I, McGregor T, Magen D. Michael M, et al. Am J Kidney Dis. 2023 Feb;81(2):145-155.e1. doi: 10.1053/j.ajkd.2022.05.012. Epub 2022 Jul 14. Am J Kidney Dis. 2023. PMID: 35843439 Free article. Clinical Trial.
RATIONALE & OBJECTIVE: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and relatively preserved kidney function. ...PLAIN-LANGUAGE SUMMARY: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease charac …
RATIONALE & OBJECTIVE: Lumasiran reduces urinary and plasma oxalate (POx) in patients with primary hyperoxaluria type 1 (PH1) and …
Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1.
Garrelfs SF, Frishberg Y, Hulton SA, Koren MJ, O'Riordan WD, Cochat P, Deschênes G, Shasha-Lavsky H, Saland JM, Van't Hoff WG, Fuster DG, Magen D, Moochhala SH, Schalk G, Simkova E, Groothoff JW, Sas DJ, Meliambro KA, Lu J, Sweetser MT, Garg PP, Vaishnaw AK, Gansner JM, McGregor TL, Lieske JC; ILLUMINATE-A Collaborators. Garrelfs SF, et al. N Engl J Med. 2021 Apr 1;384(13):1216-1226. doi: 10.1056/NEJMoa2021712. N Engl J Med. 2021. PMID: 33789010 Clinical Trial.
BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to kidney stones, nephrocalcinosis, kidney failure, and systemic oxalosis. Lumasiran, an investigational RNA interference (RNAi) therapeutic agen …
BACKGROUND: Primary hyperoxaluria type 1 (PH1) is a rare genetic disease caused by hepatic overproduction of oxalate that leads to ki …
Primary hyperoxaluria.
Lorenzo V, Torres A, Salido E. Lorenzo V, et al. Nefrologia. 2014 May 21;34(3):398-412. doi: 10.3265/Nefrologia.pre2014.Jan.12335. Epub 2014 Apr 30. Nefrologia. 2014. PMID: 24798559 Free article. Review. English, Spanish.
Primary hyperoxaluria (PH) occurs due to an autosomal recessive hereditary disorder of the metabolism of glyoxylate, which causes excessive oxalate production. ...Pre-emptive liver transplantation, or simultaneous liver and kidney transplants when there is already irrevers …
Primary hyperoxaluria (PH) occurs due to an autosomal recessive hereditary disorder of the metabolism of glyoxylate, which causes exc …
Future treatments for hyperoxaluria.
Burns Z, Knight J, Fargue S, Holmes R, Assimos D, Wood K. Burns Z, et al. Curr Opin Urol. 2020 Mar;30(2):171-176. doi: 10.1097/MOU.0000000000000709. Curr Opin Urol. 2020. PMID: 31895888 Free PMC article. Review.
PURPOSE OF REVIEW: The review of potential therapies in the treatment of hyperoxaluria is timely, given the current excitement with clinical trials and the mounting evidence of the importance of oxalate in both kidney stone and chronic kidney disease. ...
PURPOSE OF REVIEW: The review of potential therapies in the treatment of hyperoxaluria is timely, given the current excitement with …
Lumasiran: First Approval.
Scott LJ, Keam SJ. Scott LJ, et al. Drugs. 2021 Feb;81(2):277-282. doi: 10.1007/s40265-020-01463-0. Drugs. 2021. PMID: 33405070 Review.
Lumasiran (Oxlumo) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; encodes glycolate oxidase) and was developed by Alnylam Pharmaceuticals for the treatment of primary hyperoxaluria type 1 (PH1). By si …
Lumasiran (Oxlumo) is a subcutaneously administered small interfering RNA (siRNA) targeting the mRNA for hydroxyacid oxidase 1 gene (HAO1; e …
Hyperoxaluric calcium nephrolithiasis.
Asplin JR. Asplin JR. Endocrinol Metab Clin North Am. 2002 Dec;31(4):927-49. doi: 10.1016/s0889-8529(02)00030-0. Endocrinol Metab Clin North Am. 2002. PMID: 12474639 Review.
Hyperoxaluria leads to increased calcium oxalate supersaturation and calcium oxalate stone formation. Excess oxalate can arise from endogenous overproduction as in primary hyperoxaluria or from dietary sources. In the last 15 years great strides have been made in th …
Hyperoxaluria leads to increased calcium oxalate supersaturation and calcium oxalate stone formation. Excess oxalate can arise from e …
556 results